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Lipopeptides constitute a structurally diverse group of metabolites produced by various bacterial and fungal 
genera via non-ribosomal pathways [1]. Structurally they are amphiphilic molecules that comprise both 
hydrophobic and hydrophilic moieties, being the apolar component usually a alkyl chain, whereas the polar part, 
more variable, can be ionic (anionic or cationic) or non-ionic. In the past decades, research on lipopeptides has 
been focused on their antimicrobial, antitumor and surfactant activities. Amphisin is a lipoundecapeptide with an 
N-terminal -hydroxydecanoyl fatty acid side chain and a nonapeptide lactone core resulting from the cyclization 
of the Thr-3 hydroxyl group onto the C-terminal carboxylate [2]. 
In the present study, the antimicrobial activity of amphisin obtained by cultivation of Pseudomonas fluorescens
DSS73 was investigated against multidrug-resistant microorganism such as Escherichia coli, Enterococcus
faecalis, Staphylococcus epidermidis, Proteus mirabilis and Candida albicans found in gastrointestinal and 
urinary tracts. Amphisin antimicrobial activity was tested in presence or absence of metal ions. The results 
demonstrated that amphisin in the presence or absence of metal ions has a broad spectrum of action, including 
antimicrobial activity against microorganisms with multidrug-resistant profiles. Binding to amphisin of Cu2+ and 
Zn2+ ions increase the antimicrobial activity against E. coli and E. faecalis. The interaction of lipopeptide with 
lipid bilayer of bacterial membranes may be facilitated by metal ions, both by neutralizing the anionic charges 
and by favoring association with the membrane head groups. 
The results obtained suggest the possible use of this biosurfactant as an alternative antimicrobial agent in the 
medical field for applications against microorganisms responsible for diseases and infections, making it a 
suitable alternative to conventional antibiotics. 
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The growing number of resistant strains and biofilm-related infections emerging in healthcare settings and in the 
general community is a major biomedical concern. Currently, antimicrobial studies are revisiting the potential of 
old products and looking for new products with alternative modes of action. Most notably, antimicrobial peptides 
(AMPs) are receiving a lot of attention because of the widespread availability, multiple mechanisms of action, 
non-specific molecular targets, and anti-biofilm capabilities [1], [2]. 
Considering that most of the results obtained in these studies lay in scientific literature, and manual curation is 
time and resource consuming, the development of bioinformatics approaches for the systematic screening of the 
literature is of obvious interest. In particular, the reconstruction of drug interaction networks reflecting in vitro 
and in vivo results is considered useful to identify the most promising candidates for the development of 
alternative antimicrobial therapies, such as antimicrobial combinations [3], [4]. Such networks can aid in 
profiling and interpreting the activity of AMPs and the added value of antimicrobial combinations, and thus, help 
exploit their potential. 
As a first contribution to this line of analysis, this work presents a novel network reconstruction for results 
obtained by AMP-drug combinations in fighting Pseudomonas aeruginosa infections [5]. This network contains 
information about strains, combination methodologies, mode of growth, compound description (with drug and 
AMP database cross-linking) and quantification values (MICs, FICs, log reduction, etc.). So far, the network 
comprises 239 combinations, such that 83 % of the interactions pair an AMP with a non-AMP compound 
(antibiotics, enzymes, etc.), mainly traditional antibiotics. The majority (82 %) of the studies focused on the use 
of combinations on planktonic cells, and surprisingly enough, only 3 % of the studies tested the combination in 
biofilms. Furthermore, the network is dominated by a small number of highly connected nodes, namely the 
peptides colistin and polimyxin B. These are the products that are more often tested in antimicrobial 
combinations. 
The network is publicly available, and may be further explore using graph-based analysis tools. Hopefully, this 
will be a valuable resource to the design of new experiments, unveiling different mechanisms of action and 
helping in the prediction of new combinations. 
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